McKesson Corp. has announced plans to acquire a 70% majority stake in Florida Cancer Specialists & Research Institute's (FCS) Community Oncology Revitalization Enterprise Ventures (Core Ventures) for $2.49 billion. FCS physicians will retain a minority interest in the business under the deal, which marks a major step in McKesson's expansion into community-based oncology care.

McKesson $2.49B Deal For Cancer Biz : Deal Details and Strategic Importance

McKesson, a healthcare services giant, is acquiring a controlling stake in Core Ventures, a business and administrative services organization founded by FCS. McKesson CEO Brian Tyler described the acquisition as a critical move to advance community oncology care, emphasizing that it will enhance patient care, reduce costs, and accelerate clinical developments in cancer treatment.

"This milestone marks an important step forward in our efforts to advance community-based oncology care," Tyler said, noting that FCS' patient-first approach aligns with McKesson's goals.

About Florida Cancer Specialists

FCS, a physician-owned community oncology practice, has been providing services for more than 40 years. Its offerings include medical oncology, chemotherapy, clinical trials, radiation oncology, diagnostic imaging, and molecular pathology lab services. The practice, which boasts over 250 physicians and 280 advanced providers, operates nearly 100 locations across Florida.

Through its partnership with the Sarah Cannon Research Institute, FCS conducts community-based clinical trials to support the development of new oncology treatments.

Impact on McKesson’s Oncology Network

Following the acquisition, FCS will remain independently owned and will join McKesson's US Oncology Network, a platform focused on expanding local and affordable cancer care. Core Ventures will be integrated into McKesson's oncology services, furthering McKesson's reach in cancer care.

"This is a historic moment for FCS," said FCS CEO Nathan H. Walcker, highlighting the shared mission between FCS and the US Oncology Network to strengthen community-centered cancer care. "We are thrilled to partner with McKesson and join the Network."

McKesson $2.49B Deal For Cancer Biz : Legal Representation

FCS is being represented by a team from Paul Weiss Rifkind Wharton & Garrison LLP, including partners Krishna Veeraraghavan and Cullen L. Sinclair. Counsel for McKesson was not immediately available at the time of the announcement.